Core Viewpoint - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending patient lifespan [2] Group 1: Research Development - A research team led by Professor Lin Lisen from Fuzhou University and Professor Chen Xiaoyuan from the National University of Singapore published a study in Nature Nanotechnology, introducing a biohybrid chiral hydrogel that enhances postoperative GBM therapy by multi-pronged inhibition of tumor stemness [3][5] - The biohybrid chiral hydrogel is designed for intracavitary implantation after GBM tumor resection, aiming to comprehensively regulate glioblastoma stem cells (GSC) and improve postoperative treatment outcomes [5] Group 2: Mechanism and Efficacy - The hydrogel encapsulates GSC membrane-coated nanoparticles that serve as effective decoys to neutralize chemokines targeting GSC, achieving functional blockade of GSC and hydrogel infiltration [5] - The D-type chiral biohybrid hydrogel, through geometric regulation of mechanical transduction pathways, further diminishes the stemness phenotype of GSC compared to L-type and DL-type counterparts [5] - In three orthotopic GBM models, this multi-faceted GSC stemness inhibition enhances the efficacy of a gold nanoparticle-based hydrogel scaffold sensitized radiotherapy, thereby suppressing postoperative GBM recurrence [5][6]

Core Viewpoint - The study identifies BRD9 as a key regulator of glioblastoma's resistance to oncolytic virus therapy, suggesting that inhibiting BRD9 can enhance the efficacy of such treatments [4][10]. Group 1: Research Findings - The research utilized a genome-wide CRISPR screening approach to discover that BRD9 is a critical factor in tumor resistance to oncolytic virus therapy [4][8]. - Inhibition of BRD9 significantly enhances the replication and anti-tumor effects of oncolytic herpes simplex virus type 1 (oHSV1), indicating a potential therapeutic value when combined with BRD9 inhibitors [6][10]. - BRD9 interacts with RELA to regulate the expression of antiviral genes, which is crucial for the effectiveness of oHSV1 therapy [7][8]. Group 2: Clinical Implications - The study suggests that BRD9 levels could serve as a potential biomarker for predicting clinical outcomes in oHSV1 therapy for glioblastoma patients [8][10]. - The findings highlight the importance of developing strategies to target BRD9 in order to overcome the resistance seen in glioblastoma treatments [10].